Hepatitis B Trial, Recruiting NCT02883647 Sponsor: Third Affiliated Hospital, Sun Yat-Sen University Condition: Hepatitis B
Back to Hepatitis B

Hepatitis B Trial, Recruiting

NCT02883647
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been receiving antiviral treatment for hepatitis B (a type of medication called nucleoside/nucleotide analogs).
  • People whose antiviral treatment has been ongoing for at least 2 years.
  • People who had a specific hepatitis B protein (HBeAg) detected in their blood and whose hepatitis B virus levels have remained undetectable for at least 1 year after that protein converted to negative, before stopping treatment (confirm with trial site).
  • People who did not have that specific hepatitis B protein (HBeAg) detected in their blood and whose hepatitis B virus levels have remained undetectable for at least 2 years before stopping treatment (confirm with trial site).

Who may not be able to join:

  • People who have liver cirrhosis (scarring of the liver) or liver cancer (HCC).
  • People whose liver disease is being caused by something other than hepatitis B.
  • People who are currently pregnant or breastfeeding.
  • People who have HIV or a condition where the immune system does not work properly from birth.
  • People who have severe diabetes, autoimmune diseases, serious problems with other major organs, or other significant health complications.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 14 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Liang Peng, Doctor, Third Affiliated Hospital, Sun Yat-Sen University

Phone: +8613760783281

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Third Affiliated Hospital, Sun Yat-Sen University
Registry
ClinicalTrials.gov
Start date
1 January 2014
Est. completion
31 December 2024

Where this trial is recruiting

🇨🇳 China

Primary endpoints

relapse

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov